Original language | English (US) |
---|---|
Pages (from-to) | E57-E60 |
Journal | American journal of hematology |
Volume | 95 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2020 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia : Combination therapy to prevent ibrutinib flare. / Hampel, Paul J.; Call, Timothy G.; Ding, Wei; Muchtar, Eli; Kenderian, Saad S.; Wang, Yucai; Leis, Jose F.; Witzig, Thomas E.; Koehler, Amber B.; Fonder, Amie L.; Schwager, Susan M.; Rabe, Kari G.; Van Dyke, Daniel L.; Braggio, Esteban; Slager, Susan L.; Kay, Neil E.; Parikh, Sameer A.
In: American journal of hematology, Vol. 95, No. 3, 01.03.2020, p. E57-E60.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia
T2 - Combination therapy to prevent ibrutinib flare
AU - Hampel, Paul J.
AU - Call, Timothy G.
AU - Ding, Wei
AU - Muchtar, Eli
AU - Kenderian, Saad S.
AU - Wang, Yucai
AU - Leis, Jose F.
AU - Witzig, Thomas E.
AU - Koehler, Amber B.
AU - Fonder, Amie L.
AU - Schwager, Susan M.
AU - Rabe, Kari G.
AU - Van Dyke, Daniel L.
AU - Braggio, Esteban
AU - Slager, Susan L.
AU - Kay, Neil E.
AU - Parikh, Sameer A.
N1 - Funding Information: Presented as an abstract at the 24th Congress of the European Hematology Association. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
UR - http://www.scopus.com/inward/record.url?scp=85076378989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076378989&partnerID=8YFLogxK
U2 - 10.1002/ajh.25690
DO - 10.1002/ajh.25690
M3 - Letter
C2 - 31788844
AN - SCOPUS:85076378989
VL - 95
SP - E57-E60
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 3
ER -